452 related articles for article (PubMed ID: 34262796)
1. Double-edged effects of interferons on the regulation of cancer-immunity cycle.
Zhang X; Wang S; Zhu Y; Zhang M; Zhao Y; Yan Z; Wang Q; Li X
Oncoimmunology; 2021; 10(1):1929005. PubMed ID: 34262796
[TBL] [Abstract][Full Text] [Related]
2. New perspectives on type I IFNs in cancer.
Gajewski TF; Corrales L
Cytokine Growth Factor Rev; 2015 Apr; 26(2):175-8. PubMed ID: 25630967
[TBL] [Abstract][Full Text] [Related]
3. Role of interferons and other cytokines in the regulation of the immune response.
Belardelli F
APMIS; 1995 Mar; 103(3):161-79. PubMed ID: 7538771
[TBL] [Abstract][Full Text] [Related]
4. Type I and II interferons toward ideal vaccine and immunotherapy.
Temizoz B; Ishii KJ
Expert Rev Vaccines; 2021 May; 20(5):527-544. PubMed ID: 33993812
[No Abstract] [Full Text] [Related]
5. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
[TBL] [Abstract][Full Text] [Related]
6. The role of interferons in ovarian cancer progression: Hinderer or promoter?
Liu T; Li Y; Wang X; Yang X; Fu Y; Zheng Y; Gong H; He Z
Front Immunol; 2022; 13():1087620. PubMed ID: 36618371
[TBL] [Abstract][Full Text] [Related]
7. Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response.
von Locquenghien M; Rozalén C; Celià-Terrassa T
J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33393507
[TBL] [Abstract][Full Text] [Related]
8. Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts).
Gattoni A; Parlato A; Vangieri B; Bresciani M; Derna R
Clin Ter; 2006; 157(4):377-86. PubMed ID: 17051976
[TBL] [Abstract][Full Text] [Related]
9. The interferons and their receptors--distribution and regulation.
de Weerd NA; Nguyen T
Immunol Cell Biol; 2012 May; 90(5):483-91. PubMed ID: 22410872
[TBL] [Abstract][Full Text] [Related]
10. Interferons and Resistance Mechanisms in Tumors and Pathogen-Driven Diseases-Focus on the Major Histocompatibility Complex (MHC) Antigen Processing Pathway.
Massa C; Wang Y; Marr N; Seliger B
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047709
[TBL] [Abstract][Full Text] [Related]
11. Induction and regulation of IFNs during viral infections.
Malmgaard L
J Interferon Cytokine Res; 2004 Aug; 24(8):439-54. PubMed ID: 15320958
[TBL] [Abstract][Full Text] [Related]
12. STING: a master regulator in the cancer-immunity cycle.
Zhu Y; An X; Zhang X; Qiao Y; Zheng T; Li X
Mol Cancer; 2019 Nov; 18(1):152. PubMed ID: 31679519
[TBL] [Abstract][Full Text] [Related]
13. Interferons and their stimulated genes in the tumor microenvironment.
Cheon H; Borden EC; Stark GR
Semin Oncol; 2014 Apr; 41(2):156-73. PubMed ID: 24787290
[TBL] [Abstract][Full Text] [Related]
14. Type I interferons as regulators of human antigen presenting cell functions.
Gessani S; Conti L; Del Cornò M; Belardelli F
Toxins (Basel); 2014 May; 6(6):1696-723. PubMed ID: 24866026
[TBL] [Abstract][Full Text] [Related]
15. Type I interferons in pancreatic cancer and development of new therapeutic approaches.
Blaauboer A; Sideras K; van Eijck CHJ; Hofland LJ
Crit Rev Oncol Hematol; 2021 Mar; 159():103204. PubMed ID: 33387625
[TBL] [Abstract][Full Text] [Related]
16. The stimulator of interferon genes (STING) agonists for treating acute myeloid leukemia (AML): current knowledge and future outlook.
Song X; Peng Y; Wang X; Chen Q; Lan X; Shi F
Clin Transl Oncol; 2023 Jun; 25(6):1545-1553. PubMed ID: 36587109
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effect of adenosine on adaptive antitumor immunity and intervention strategies.
Wang L; Zhang W; Zhang J; Zheng M; Pan X; Guo H; Ding L
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Sep; 52(5):567-577. PubMed ID: 37916308
[TBL] [Abstract][Full Text] [Related]
18. Empowering therapeutic antibodies with IFN-α for cancer immunotherapy.
Guo J; Xiao Y; Iyer R; Lu X; Lake M; Ladror U; Harlan J; Samanta T; Tomlinson M; Bukofzer G; Donawho C; Shoemaker A; Huang TH
PLoS One; 2019; 14(8):e0219829. PubMed ID: 31393905
[TBL] [Abstract][Full Text] [Related]
19. Interferons as Essential Modulators of Atherosclerosis.
Boshuizen MC; de Winther MP
Arterioscler Thromb Vasc Biol; 2015 Jul; 35(7):1579-88. PubMed ID: 25953648
[TBL] [Abstract][Full Text] [Related]
20. The host STING pathway at the interface of cancer and immunity.
Corrales L; McWhirter SM; Dubensky TW; Gajewski TF
J Clin Invest; 2016 Jul; 126(7):2404-11. PubMed ID: 27367184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
